More Vaccine Disappointment For Sanofi As First C Diff Toxoid Vaccine Fails
A second dose of bad news for Sanofi's vaccines unit sees its C. difficile vaccine dropped after a Phase III study was deemed unlikely to succeed.
You may also be interested in...
Company believes there is a path forward for developing ribaxamase in Phase III, based on discussions with the FDA, but deaths in Phase II meant loss of breakthrough designation.
Sanofi's major investments in vaccine manufacturing are continuing with the expansion of its Toronto, Canada facility, to be completed in 2021.
The French drug manufacturer admits the world’s first dengue vaccine may be harmful when administered to individuals not previously infected with the disease.